Skysona

FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports
Fierce Pharma
Mon, 12/2/24 - 07:46 pm
Bluebird Bio
Skysona
gene therapy
FDA
blood cancer
cALD
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action
Medpage Today
Wed, 11/27/24 - 09:59 pm
Bluebird Bio
Skysona
FDA
myelodysplastic syndrome
AML
cALD
New data underline cancer risk of Bluebird therapy for brain disease
BioPharma Dive
Thu, 10/10/24 - 11:15 am
Bluebird Bio
gene therapy
Skysona
cALD
Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears
Fierce Pharma
Tue, 08/8/23 - 11:33 am
Bluebird Bio
Zynteglo
Skysona
FDA
sickle cell disease
gene therapy
Gene therapy is saving lives, but key challenges to realize its full potential
MedCity News
Thu, 10/20/22 - 10:30 am
gene therapy
Novartis
Zolgensma
Roctavian
Zynteglo
Skysona
Bluebird wins FDA approval of gene therapy for rare brain disorder
BioPharma Dive
Sun, 09/18/22 - 10:23 pm
Bluebird Bio
gene therapy
cALD
Skysona
FDA
Bluebird, winding down in Europe, withdraws another rare disease gene therapy
BioPharma Dive
Thu, 10/21/21 - 11:17 pm
Bluebird Bio
gene therapy
Europe
Skysona
cerebral adrenoleukodystrophy
Bluebird, with little fanfare, is first to bring a second gene therapy to market
BioPharma Dive
Wed, 07/21/21 - 08:43 pm
Europe
Bluebird Bio
Skysona
cerebral adrenoleukodystrophy
gene therapy
Bluebird’s new gene therapy among three new EMA OKs ahead of FDA
Endpoints
Fri, 05/21/21 - 10:56 am
gene therapy
Bluebird Bio
EMA
GSK
Vir
COVID-19
Skysona
monoclonal antibodies
Bylvay